Amgen Inc. (AMGN-Q) Stock Predictions - Stockchase
WATCH LIST
95
Amgen Inc. (AMGN-Q)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Amgen Inc.

AMGN-Q

22 watching          
Join the Discussion

Amgen Inc. (AMGN-Q) SAVE Mar, 25, 2019, 8:32 pm

186.59 0.11 (0.06%)

About Amgen Inc. (AMGN-Q)

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. More at Wikipedia

What the experts are saying about AMGN-Q



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Amgen Inc.(AMGN-Q) 

December 3, 2018

(A Top Pick Jul 05/18, Up 10%) He held onto this over the summer, despite expecting autumnal volatility. It's a diversified biotech and big in bio-similars, so AMGN would benefit from an uptick here. It's reasonably priced.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Jul 05/18, Up 10%) He held onto this over the summer, despite expecting autumnal volatility. It's a diversified biotech and big in bio-similars, so AMGN would benefit from an uptick here. It's reasonably priced.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$202.930
Owned Owned
Yes

WAIT
Amgen Inc.(AMGN-Q) 

October 19, 2018

Had owned it for a number of years but sold it recently.  The growth trajectory going forward was slowing.  Still pretty cheap and great cash flow.  For him to get back into this stock, it would have to be significantly lower. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Had owned it for a number of years but sold it recently.  The growth trajectory going forward was slowing.  Still pretty cheap and great cash flow.  For him to get back into this stock, it would have to be significantly lower. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bryden Teich

Portfolio , Avenue Investment Ma...

Price Price
$201.800
Owned Owned
No

TOP PICK
Amgen Inc.(AMGN-Q) 

July 5, 2018

One of the leading biotech firms. They have a number of new drugs that came out. Dividend yield of 2.8%. Market cap of $124 billion.  (Analysts’ price target is $196.95)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the leading biotech firms. They have a number of new drugs that came out. Dividend yield of 2.8%. Market cap of $124 billion.  (Analysts’ price target is $196.95)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$187.360
Owned Owned
Yes

COMMENT
Amgen Inc.(AMGN-Q) 

November 2, 2017

Pharmaceutical stocks have had a much more difficult time because of the presidential election, a time when they usually fall. However, they've bounced back as much as they normally do. This is not expensive. Trading at about 14X earnings and pays a nice dividend yield. Has some really great drugs in their pipeline. It continues to outperform on an earnings basis. He really likes this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Pharmaceutical stocks have had a much more difficult time because of the presidential election, a time when they usually fall. However, they've bounced back as much as they normally do. This is not expensive. Trading at about 14X earnings and pays a nice dividend yield. Has some really great drugs in their pipeline. It continues to outperform on an earnings basis. He really likes this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$172.410
Owned Owned
Yes

HOLD
Amgen Inc.(AMGN-Q) 

October 26, 2017

Sell?This company has a very high free cash flow yield and is very profitable. Have some drugs coming off patent, but biotech drugs generally survive the loss of patents because the drugs are hard to copy. Thinks you will be fine with this in the long run. 2.6% dividend yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Sell?This company has a very high free cash flow yield and is very profitable. Have some drugs coming off patent, but biotech drugs generally survive the loss of patents because the drugs are hard to copy. Thinks you will be fine with this in the long run. 2.6% dividend yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Burke

CEO & CIO, Burke Financial Stra...

Price Price
$176.520
Owned Owned
Unknown

HOLD
Amgen Inc.(AMGN-Q) 

October 10, 2017

Hold or Sell? Within biotech and picking a single name, this company would be the way to do it. They are more diversified. They’ve had a few good quarters in a row beating earnings, and are still only trading at 14-16 levels. Putting up pretty good growth. Now that we are more comfortable with interest rates not going to the moon, that takes off the risk, opening up the door to make this more investable.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Hold or Sell? Within biotech and picking a single name, this company would be the way to do it. They are more diversified. They’ve had a few good quarters in a row beating earnings, and are still only trading at 14-16 levels. Putting up pretty good growth. Now that we are more comfortable with interest rates not going to the moon, that takes off the risk, opening up the door to make this more investable.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$185.790
Owned Owned
Unknown

HOLD
Amgen Inc.(AMGN-Q) 

September 19, 2017

A fairly inexpensive stock from a valuation standpoint. One of the granddaddies of biotech. This is probably a good hold here. The whole biotech area is getting a bit of a bid under it. There has been more positive action within that whole sector.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A fairly inexpensive stock from a valuation standpoint. One of the granddaddies of biotech. This is probably a good hold here. The whole biotech area is getting a bit of a bid under it. There has been more positive action within that whole sector.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$186.320
Owned Owned
No

HOLD
Amgen Inc.(AMGN-Q) 

September 14, 2017

They create drugs similar to other bio-similar drugs.  The competitive threats in biologics are a little bit similar.  They got approval this morning for a biologic drug.  He would like to see them consolidate here.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They create drugs similar to other bio-similar drugs.  The competitive threats in biologics are a little bit similar.  They got approval this morning for a biologic drug.  He would like to see them consolidate here.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$189.440
Owned Owned
Unknown

COMMENT
Amgen Inc.(AMGN-Q) 

August 17, 2017

A fabulous company and has done very well, but their drugs are very mature and make up a very large piece of their total revenue and portfolio. They are spending a lot of money on R&D which has some promise, but no guarantee that they are going to be able to replace the revenue flow. The stock is trading at about 12X earnings. Prefers something that has more current opportunities and a deeper pipeline.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A fabulous company and has done very well, but their drugs are very mature and make up a very large piece of their total revenue and portfolio. They are spending a lot of money on R&D which has some promise, but no guarantee that they are going to be able to replace the revenue flow. The stock is trading at about 12X earnings. Prefers something that has more current opportunities and a deeper pipeline.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$167.810
Owned Owned
Unknown

COMMENT
Amgen Inc.(AMGN-Q) 

July 24, 2017

Trading range would be between $129 and about $180. Generally, he likes breakouts, but the chart shows that breakouts in the past have failed. He would be a little concerned with this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Trading range would be between $129 and about $180. Generally, he likes breakouts, but the chart shows that breakouts in the past have failed. He would be a little concerned with this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Keith Richards

Portfolio , ValueTrend Wealth Ma...

Price Price
$181.060
Owned Owned
Unknown

COMMENT
Amgen Inc.(AMGN-Q) 

June 9, 2017

He would advocate Gilead (GILD-Q) instead. It has one of the strongest hepatitis C franchises in the world. This stock is down 58% from its all-time high and trading at less than 9X earnings with a wonderful management team.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He would advocate Gilead (GILD-Q) instead. It has one of the strongest hepatitis C franchises in the world. This stock is down 58% from its all-time high and trading at less than 9X earnings with a wonderful management team.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Dietze

Founder, P, Point View Wealth Ma...

Price Price
$164.060
Owned Owned
Unknown

HOLD
Amgen Inc.(AMGN-Q) 

May 19, 2017

He likes this as an investment. It could be a core health care holding in any portfolio. They’ve generated tremendous cash flow and have a very strong balance sheet.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He likes this as an investment. It could be a core health care holding in any portfolio. They’ve generated tremendous cash flow and have a very strong balance sheet.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Petrides

Managing D, Point View Wealth Ma...

Price Price
$156.510
Owned Owned
Unknown

DON'T BUY
Amgen Inc.(AMGN-Q) 

May 17, 2017

To take out the idiosyncratic risk, he would play Biotechs through the ETF iShares NASDAQ BioTech (IBB-Q). They all have their individual pipelines, but ultimately are going to trade very similarly, except for idiosyncratic risk, which you want to avoid. He wouldn’t advocate buying Biotech or Pharma right now given the pricing pressure of the policy measures, etc.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

To take out the idiosyncratic risk, he would play Biotechs through the ETF iShares NASDAQ BioTech (IBB-Q). They all have their individual pipelines, but ultimately are going to trade very similarly, except for idiosyncratic risk, which you want to avoid. He wouldn’t advocate buying Biotech or Pharma right now given the pricing pressure of the policy measures, etc.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$157.060
Owned Owned
Unknown

HOLD
Amgen Inc.(AMGN-Q) 

May 10, 2017

A larger cap pure play biotech company, that has a deep pipeline in bio-similars. He doesn’t see competition in the near term for their drug Enbrow (?), which is 3%-2.5% of their top line. They have some drugs that have come off patent, and need to backfill on the top line. One way they were looking to do this was through the PCSK9 drug, a cardio cholesterol lowering drug. Initially they came out with positive results. He bought a Put for some protection. A great balance sheet and an OK yield and modest growth. He is monitoring this. Rates it as a very strong Hold.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A larger cap pure play biotech company, that has a deep pipeline in bio-similars. He doesn’t see competition in the near term for their drug Enbrow (?), which is 3%-2.5% of their top line. They have some drugs that have come off patent, and need to backfill on the top line. One way they were looking to do this was through the PCSK9 drug, a cardio cholesterol lowering drug. Initially they came out with positive results. He bought a Put for some protection. A great balance sheet and an OK yield and modest growth. He is monitoring this. Rates it as a very strong Hold.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$160.510
Owned Owned
Yes

COMMENT
Amgen Inc.(AMGN-Q) 

April 13, 2017

A great company. It is considered a biotech company, but has a market cap of over $1 billion. Trading at only 13X earnings and has a great free cash flow yield of almost 12%. He feels their pipeline is really strong and that the value of the company is 20% higher than it is here.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A great company. It is considered a biotech company, but has a market cap of over $1 billion. Trading at only 13X earnings and has a great free cash flow yield of almost 12%. He feels their pipeline is really strong and that the value of the company is 20% higher than it is here.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$161.610
Owned Owned
Yes

Showing 1 to 15 of 95 entries
Successfully Saved Company
Successfully Saved Company
0+
JOIN THE DISCUSSION
0 comments in the last 7 days